Glenmark Life Sciences Past Earnings Performance
Past criteria checks 2/6
Glenmark Life Sciences has been growing earnings at an average annual rate of 7.9%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 4.3% per year. Glenmark Life Sciences's return on equity is 16.7%, and it has net margins of 19.2%.
Key information
7.9%
Earnings growth rate
4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.3% |
| Return on equity | 16.7% |
| Net Margin | 19.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Glenmark Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 22,049 | 4,235 | 2,745 | 0 |
| 30 Jun 24 | 22,934 | 4,469 | 2,669 | 0 |
| 31 Mar 24 | 22,832 | 4,709 | 2,701 | 0 |
| 31 Dec 23 | 23,679 | 5,193 | 2,391 | 0 |
| 30 Sep 23 | 23,359 | 5,055 | 2,166 | 0 |
| 30 Jun 23 | 22,498 | 4,937 | 1,879 | 0 |
| 31 Mar 23 | 21,612 | 4,670 | 1,896 | 0 |
| 31 Dec 22 | 20,540 | 4,195 | 1,812 | 0 |
| 30 Sep 22 | 20,357 | 4,182 | 1,768 | 0 |
| 30 Jun 22 | 20,882 | 4,265 | 1,722 | 0 |
| 31 Mar 22 | 21,232 | 4,187 | 1,744 | 0 |
| 31 Dec 21 | 20,763 | 4,245 | 1,733 | 0 |
| 30 Sep 21 | 20,541 | 4,142 | 1,669 | 0 |
| 30 Jun 21 | 20,131 | 3,714 | 1,608 | 0 |
| 31 Mar 21 | 18,852 | 3,516 | 1,553 | 0 |
| 31 Mar 20 | 15,373 | 3,131 | 1,545 | 0 |
| 31 Mar 19 | 8,864 | 1,956 | 1,169 | 0 |
| 31 Mar 18 | 2 | -4 | 2 | 0 |
Quality Earnings: GLS has high quality earnings.
Growing Profit Margin: GLS's current net profit margins (19.2%) are lower than last year (21.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLS's earnings have grown by 7.9% per year over the past 5 years.
Accelerating Growth: GLS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GLS had negative earnings growth (-16.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: GLS's Return on Equity (16.7%) is considered low.